The controversial role of ABC transporters in clinical oncology

Essays in Biochemistry

Volumn 50, Issue 1, 2011, Pages 209-232

  Tamaki, Akina ^a   Ierano, Caterina ^a   Szakacs, Gergely ^b   Robey, Robert W ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF ENZYMOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT;

HUMAN; NEOPLASM; ONCOLOGY; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 84856282091     PISSN: 00711365     EISSN: None     Source Type: Journal    
DOI: 10.1042/BSE0500209     Document Type: Article

References (101)

1. Aller, S., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P., Trinh, Y., Zhang, Q., Urbatsch, I. and Chang, G. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718-1722
2. Boumendjel, A., Boutonnat, J. and Robert, J. (2009) ABC transporters and multidrug resistance. John Wiley and Sons, Hoboken
3. Szakács, G., Paterson, J., Ludwig, J., Booth-Genthe, C. and Gottesman, M. (2006) Targeting multi-drug resistance in cancer. Nat. Rev. Drug Discovery 5, 219-234
4. Cordon-Cardo, C., O'Brien, J.P., Boccia, J., Casals, D., Bertino, J.R. and Melamed, M.R. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38, 1277-1287
5. Fetsch, P., Abati, A., Litman, T., Morisaki, K., Honjo, Y., Mittal, K. and Bates, S. (2006) Localization of the ABCG2 mitoxantrone resistance- associated protein in normal tissues. Cancer Lett. 235, 84-92
6. Maliepaard, M., Scheffer, G., Faneyte, I., van Gastelen, M., Pijnenborg, A., Schinkel, A., van De Vijver, M., Scheper, R. and Schellens, J. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464
7. Zhou, S., Schuetz, J., Bunting, K., Colapietro, A., Sampath, J., Morris, J., Lagutina, I., Grosveld, G., Osawa, M., Nakauchi, H. and Sorrentino, B. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7, 1028-1034
8. Deeley, R. and Cole, S. (2006) Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 580, 1103-1111
9. Wijnholds, J., Scheffer, G., van der Valk, M., van der Valk, P., Beijnen, J., Scheper, R. and Borst, P. (1998) Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J. Exp. Med. 188, 797-808
10. Wijnholds, J., de Lange, E., Scheffer, G., van den Berg, D., Mol, C., van der Valk, M., Schinkel, A., Scheper, R., Breimer, D. and Borst, P. (2000) Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105, 279-285
11. Polgar, O. and Bates, S. (2005) ABC transporters in the balance: is there a role in multidrug resistance? Biochem. Soc. Trans. 33, 241-245
12. Leith, C., Kopecky, K., Chen, I., Eijdems, L., Slovak, M., McConnell, T., Head, D., Weick, J., Grever, M., Appelbaum, F. and Willman, C. (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 94, 1086-1099
13. Legrand, O., Simonin, G., Perrot, J.Y., Zittoun, R. and Marie, J.P. (1998) Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91, 4480-4488
14. Wilson, C., Davidson, G., Martin, S., Andries, E., Potter, J., Harvey, R., Ar, K., Xu, Y., Kopecky, K., Ankerst, D. et al. (2006) Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108, 685-696
15. Benderra, Z., Faussat, A.M., Sayada, L., Perrot, J.Y., Chaoui, D., Marie, J.P. and Legrand, O. (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin. Cancer Res. 10, 7896-7902
16. van den Heuvel-Eibrink, M., van der Holt, B., Burnett, A., Knauf, W., Fey, M., Verhoef, G., Vellenga, E., Ossenkoppele, G., Löwenberg, B. and Sonneveld, P. (2007) CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann. Hematol. 86, 329-337
17. Burger, H., Foekens, J., Look, M., Meijer-van Gelder, M., Klijn, J., Wiemer, E., Stoter, G. and Nooter, K. (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 9, 827-836
18. Trock, B.J., Leonessa, F. and Clarke, R. (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. 89, 917-931
19. Penson, R.T., Oliva, E., Skates, S.J., Glyptis, T., Fuller, A.F., Jr, Goodman, A. and Seiden, M.V. (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol. Oncol. 93, 98-106
20. van den Heuvel-Eibrink, M.M., van der Holt, B., Burnett, A.K., Knauf, W.U., Fey, M.F., Verhoef, G.E., Vellenga, E., Ossenkoppele, G.J., Lowenberg, B. and Sonneveld, P. (2007) CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann. Hematol. 86, 329-337
21. Michieli, M., Damiani, D., Ermacora, A., Masolini, P., Raspadori, D., Visani, G., Scheper, R.J. and Baccarani, M. (1999) P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br. J. Haematol. 104, 328-335
22. Filipits, M., Pohl, G., Rudas, M., Dietze, O., Lax, S., Grill, R., Pirker, R., Zielinski, C., Hausmaninger, H., Kubista, E. et al. (2005) Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 23, 1161-1168
23. Hsia, T., Lin, C., Wang, J., Ho, S. and Kao, A. (2002) Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 180, 173-179
24. Li, J., Li, Z., Yu, L., Bao, Q., Wu, J., Shi, S. and Li, X. (2010) Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 69, 116-122
25. Galimberti, S., Guerrini, F., Palumbo, G., Consoli, U., Fazzi, R., Morabito, F., Santini, V. and Petrini, M. (2004) Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk. Res. 28, 367-372
26. van der Kolk, D., Vellenga, E., Scheffer, G., Müller, M., Bates, S., Scheper, R. and de Vries, E. (2002) Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99, 3763-3770
27. Abbott, B., Colapietro, A., Barnes, Y., Marini, F., Andreeff, M. and Sorrentino, B. (2002) Low levels of ABCG2 expression in adult AML blast samples. Blood 100, 4594-4601
28. van der Pol, M., Broxterman, H., Pater, J., Feller, N., van der Maas, M., Weijers, G., Scheffer, G., Allen, J., Scheper, R., van Loevezijn, A. et al. (2003) Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 88, 134-147
29. Uggla, B., Stahl, E., Wagsater, D., Paul, C., Karlsson, M.G., Sirsjo, A. and Tidefelt, U. (2005) BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk. Res. 29, 141-146
30. Suvannasankha, A., Minderman, H., O'Loughlin, K.L., Nakanishi, T., Greco, W.R., Ross, D.D. and Baer, M.R. (2004) Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia 18, 1252-1257
31. Steinbach, D., Sell, W., Voigt, A., Hermann, J., Zintl, F. and Sauerbrey, A. (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16, 1443-1447
32. Ota, S., Ishii, G., Goto, K., Kubota, K., Kim, Y., Kojika, M., Murata, Y., Yamazaki, M., Nishiwaki, Y., Eguchi, K. and Ochiai, A. (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64, 98-104
33. Kim, Y., Ishii, G., Goto, K., Ota, S., Kubota, K., Murata, Y., Mishima, M., Saijo, N., Nishiwaki, Y. and Ochiai, A. (2009) Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65, 105-111
34. Dean, M., Fojo, T. and Bates, S. (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284
35. Polgar, O. and Bates, S.E. (2005) ABC transporters in the balance: is there a role in multidrug resistance? Biochem. Soc. Trans. 33, 241-245
36. Wattel, E., Solary, E., Hecquet, B., Caillot, D., Ifrah, N., Brion, A., Milpied, N., Janvier, M., Guerci, A., Rochant, H. et al. (1999) Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP): updated results of a randomized study. Groupe Francais des Myelodysplasies (GFM) and Groupe GOELAMS. Adv. Exp. Med. Biol. 457, 35-46
37. List, A.F., Kopecky, K.J., Willman, C.L., Head, D.R., Persons, D.L., Slovak, M.L., Dorr, R., Karanes, C., Hynes, H.E., Doroshow, J.H. et al. (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98, 3212-3220
38. Wilson, W., Bates, S., Fojo, A., Bryant, G., Zhan, Z., Regis, J., Wittes, R., Jaffe, E., Steinberg, S. and Herdt, J. (1995) Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. Clin. Oncol. 13, 1995-2004
39. Chauncey, T., Gundacker, H., Shadman, M., List, A., Dakhil, S., Erba, H., Slovak, M., Chen, I., Willman, C., Kopecky, K. and Appelbaum, F. (2010) Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br. J. Haematol. 148, 48-58
40. Twentyman, P. and Bleehen, N. (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur. J. Cancer 27, 1639-1642
41. te Boekhorst, P., van Kapel, J., Schoester, M. and Sonneveld, P. (1992) Reversal of typical multid-rug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother. Pharmacol. 30, 238-242
42. Bates, S., Kang, M., Meadows, B., Bakke, S., Choyke, P., Merino, M., Goldspiel, B., Chico, I., Smith, T., Chen, C. et al. (2001) A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 92, 1577-1590
43. Wandel, C., Kim, R., Kajiji, S., Guengerich, P., Wilkinson, G. and Wood, A. (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 59, 3944-3948
44. Friedenberg, W., Rue, M., Blood, E., Dalton, W., Shustik, C., Larson, R., Sonneveld, P. and Greipp, P. (2006) Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 106, 830-838
45. Baer, M.R., George, S.L., Dodge, R.K., O'Loughlin, K.L., Minderman, H., Caligiuri, M.A., Anastasi, J., Powell, B.L., Kolitz, J.E., Schiffer, C.A. et al. (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100, 1224-1232
46. ten Tije, A., Synold, T., Spicer, D., Verweij, J., Doroshow, J. and Sparreboom, A. (2003) Effect of valspodar on the pharmacokinetics of unbound paclitaxel. Invest. New Drugs 21, 291-298
47. Bates, S., Bakke, S., Kang, M., Robey, R., Zhai, S., Thambi, P., Chen, C., Patil, S., Smith, T., Steinberg, S. et al. (2004) A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin. Cancer Res. 10, 4724-4733
48. Kolitz, J.E., George, S.L., Dodge, R.K., Hurd, D.D., Powell, B.L., Allen, S.L., Velez-Garcia, E., Moore, J.O., Shea, T.C., Hoke, E. et al. (2004) Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J. Clin. Oncol. 22, 4290-4301
49. Minderman, H., O'Loughlin, K.L., Pendyala, L. and Baer, M.R. (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 10, 1826-1834
50. Seiden, M., Swenerton, K., Matulonis, U., Campos, S., Rose, P., Batist, G., Ette, E., Garg, V., Fuller, A., Harding, M. and Charpentier, D. (2002) A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol. Oncol. 86, 302-310
51. Bramwell, V., Morris, D., Ernst, D., Hings, I., Blackstein, M., Venner, P., Ette, E., Harding, M., Waxman, A. and Demetri, G. (2002) Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin. Cancer Res. 8, 383-393
52. de Bruin, M., Miyake, K., Litman, T., Robey, R. and Bates, S.E. (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 146, 117-126
53. Robey, R.W., Steadman, K., Polgar, O., Morisaki, K., Blayney, M., Mistry, P. and Bates, S.E. (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 64, 1242-1246
54. Kuppens, I., Witteveen, E., Jewell, R., Radema, S., Paul, E., Mangum, S., Beijnen, J., Voest, E. and Schellens, J. (2007) A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin. Cancer Res. 13, 3276-3285
55. + lymphocytes after oral and intravenous administration. Clin. Cancer Res. 6, 4186-4191
56. Abraham, J., Edgerly, M., Wilson, R., Chen, C., Rutt, A., Bakke, S., Robey, R., Dwyer, A., Goldspiel, B., Balis, F. et al. (2009) A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin. Cancer Res. 15, 3574-3582
57. Nobili, S., Landini, I., Giglioni, B. and Mini, E. (2006) Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 7, 861-879
58. Fox, E. and Bates, S. (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 7, 447-459
59. Lancet, J., Baer, M., Duran, G., List, A., Fielding, R., Marcelletti, J., Multani, P. and Sikic, B. (2009) A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk. Res. 33, 1055-1061
60. Gerrard, G., Payne, E., Baker, R., Jones, D., Potter, M., Prentice, H., Ethell, M., McCullough, H., Burgess, M., Mehta, A. and Ganeshaguru, K. (2004) Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89, 782-790
61. Morschhauser, F., Zinzani, P., Burgess, M., Sloots, L., Bouafia, F. and Dumontet, C. (2007) Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk. Lymphoma 48, 708-715
62. Ruff, P., Vorobiof, D., Jordaan, J., Demetriou, G., Moodley, S., Nosworthy, A., Werner, I., Raats, J. and Burgess, L. (2009) A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother. Pharmacol. 64, 763-768
63. van Zuylen, L., Sparreboom, A., van der Gaast, A., van der Burg, M., van Beurden, V., Bol, C., Woestenborghs, R., Palmer, P. and Verweij, J. (2000) The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin. Cancer Res. 6, 1365-1371
64. Robey, R., Shukla, S., Finley, E., Oldham, R., Barnett, D., Ambudkar, S., Fojo, T. and Bates, S. (2008) Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®. Biochem. Pharmacol. 75, 1302-1312
65. Oldham, R., Reid, W., Preisler, H. and Barnett, D. (1998) A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer. Cancer Biother. Radiopharm. 13, 71-80
66. Oldham, R., Reid, W. and Barnett, D. (2000) Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancers. Cancer Biother. Radiopharm. 15, 153-159
67. Pajic, M., Iyer, J., Kersbergen, A., van der Burg, E., Nygren, A., Jonkers, J., Borst, P. and Rottenberg, S. (2009) Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res. 69, 6396-6404
68. Rottenberg, S., Jaspers, J., Kersbergen, A., van der Burg, E., Nygren, A., Zander, S., Derksen, P., de Bruin, M., Zevenhoven, J., Lau, A. et al. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U.S.A. 105, 17079-17084
69. Holló, Z., Homolya, L., Hegedûs, T., Müller, M., Szakács, G., Jakab, K., Antal, F. and Sarkadi, B. (1998) Parallel functional and immunological detection of human multidrug resistance proteins, P-glycoprotein and MRP1. Anticancer Res. 18, 2981-2987
70. + cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 93, 306-314
71. 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9, 650-656
72. Patel, K. and Tannock, I. (2009) The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer 9, 356
73. Cusatis, G., Gregorc, V., Li, J., Spreafico, A., Ingersoll, R., Verweij, J., Ludovini, V., Villa, E., Hidalgo, M., Sparreboom, A. and Baker, S. (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst. 98, 1739-1742
74. Müller, P., Dally, H., Klappenecker, C., Edler, L., Jäger, B., Gerst, M., Spiegelhalder, B., Tuengerthal, S., Fischer, J., Drings, P. et al. (2009) Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int. J. Cancer 124, 1669-1674
75. Han, J., Lim, H., Yoo, Y., Shin, E., Park, Y., Lee, S., Lee, J., Lee, D., Kim, H. and Lee, J. (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical out-come in patients with advanced non-small cell lung cancer. Cancer 110, 138-147
76. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. and Brinkmann, U. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 3473-3478
77. Jamroziak, K., Młynarski, W., Balcerczak, E., Mistygacz, M., Trelinska, J., Mirowski, M., Bodalski, J. and Robak, T. (2004) Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. 72, 314-321
78. Sparreboom, A., Gelderblom, H., Marsh, S., Ahluwalia, R., Obach, R., Principe, P., Twelves, C., Verweij, J. and McLeod, H. (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 76, 38-44
79. Aragon-Ching, J. and Zujewski, J. (2007) CNS metastasis: an old problem in a new guise. Clin. Cancer Res. 13, 1644-1647
80. Dohse, M., Scharenberg, C., Shukla, S., Robey, R., Volkmann, T., Deeken, J., Brendel, C., Ambudkar, S., Neubauer, A. and Bates, S. (2010) Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib and dasatinib. Drug Metab. Dispos. 38, 1371-1380
81. Polli, J., Olson, K., Chism, J., John-Williams, L., Yeager, R., Woodard, S., Otto, V., Castellino, S. and Demby, V. (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl] amino} methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab. Dispos. 37, 439-442
82. Lagas, J., van Waterschoot, R., Sparidans, R., Wagenaar, E., Beijnen, J. and Schinkel, A. (2010) Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol. Cancer Ther. 9, 319-326
83. Lagas, J., van Waterschoot, R., van Tilburg, V., Hillebrand, M., Lankheet, N., Rosing, H., Beijnen, J. and Schinkel, A. (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 15, 2344-2351
84. -/- (triple-knockout) and wild-type mice. Mol. Cancer Ther. 7, 2280-2287
85. Bauer, M., Karch, R., Neumann, F., Wagner, C., Kletter, K., Müller, M., Löscher, W., Zeitlinger, M. and Langer, O. (2010) Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J. Cereb. Blood Flow Metab. 30, 510-515
86. 11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl. Med. Biol. 32, 87-93
87. 11C-verapamil in the brain: studies of healthy humans. J. Nucl. Med. 50, 1267-1275
88. 11C-N-desmethyl-loperamide. J. Nucl. Med. 51, 559-566
89. Rumpold, H., Wolf, A.M., Gruenewald, K., Gastl, G., Gunsilius, E. and Wolf, D. (2005) RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp. Hematol. 33, 767-775
90. Brendel, C., Scharenberg, C., Dohse, M., Robey, R.W., Bates, S.E., Shukla, S., Ambudkar, S.V., Wang, Y., Wennemuth, G., Burchert, A. et al. (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21, 1267-1275
91. Hegedus, C., Ozvegy-Laczka, C., Szakács, G. and Sarkadi, B. (2009) Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors? Curr. Cancer Drug Targets 9, 252-272
92. 11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl. Med. Biol. 36, 643-649
93. 11C]XR9576 to assess the function of drug efflux transporters using PET. Ann. Nucl. Med. 24, 403-412
94. Szakacs, G., To, K.K. W., Polgar, O., Robey, R.W. and Bates, S.E. (2009) Multidrug resistance mediated by MDR-ABC transporters. In Drug Resistance in Cancer Cells (Mehta, K. and Siddik, Z.H., eds), Springer, New York
95. Liu Yin, J.A., Wheatley, K., Rees, J.K. and Burnett, A.K. (2001) Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br. J. Haematol. 113, 713-726
96. Sonneveld, P., Suciu, S., Weijermans, P., Beksac, M., Neuwirtova, R., Solbu, G., Lokhorst, H., van der Lelie, J., Dohner, H., Gerhartz, H. et al. (2001) Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br. J. Haematol. 115, 895-902
97. van der Holt, B., Lowenberg, B., Burnett, A.K., Knauf, W.U., Shepherd, J., Piccaluga, P.P., Ossenkoppele, G.J., Verhoef, G.E., Ferrant, A., Crump, M. et al. (2005) The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646-2654
98. Joly, F., Joly, F., Mangioni, C., Nicoletto, M., Manikhas, G.M., Walker, J., Mietlowski, W., Jones, G., Wysowskyj, H. and Dugan, M. (2002) A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806
99. Greenberg, P.L., Lee, S.J., Advani, R., Tallman, M.S., Sikic, B.I., Letendre, L., Dugan, K., Lum, B., Chin, D.L., Dewald, G. et al. (2004) Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J. Clin. Oncol. 22, 1078-1086
100. Saeki, T., Nomizu, T., Toi, M., Ito, Y., Noguchi, S., Kobayashi, T., Asaga, T., Minami, H., Yamamoto, N., Aogi, K. et al. (2007) Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J. Clin. Oncol. 25, 411-417
101. Cripe, L.D., Uno, H., Paietta, E.M., Litzow, M.R., Ketterling, R.P., Bennett, J.M., Rowe, J.M., Lazarus, H.M., Luger, S. and Tallman, M.S. (2010) Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116, 4077-4085